SUMO3
Small ubiquitin-related modifier 3
Also known as: SMT3A, SMT3H1, SUMO3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P55854
- Gene
- SUMO3
- Ensembl
- ENSG00000184900
- Chromosome
- 21
- Canonical length
- 103 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nuclear bodies,Calyx,Connecting piece,Flagellar centriole
OverviewNCBI Gene
This gene encodes a member of the small ubiquitin-related modifier (SUMO) family of eukaryotic proteins. The encoded protein is covalently conjugated to other proteins via a post-translation modification known as sumoylation. Sumoylation may play a role in a wide variety of cellular processes, including nuclear transport, DNA replication and repair, mitosis, transcriptional regulation, and signal transduction. Alternatively spliced transcript variants encoding distinct proteins have been described. [provided by RefSeq, Feb 2014]
Canonical amino-acid sequenceUniProt
103 residues, UniProt reviewed canonical sequence.
>P55854|SUMO3
1 MSEEKPKEGV KTENDHINLK VAGQDGSVVQ FKIKRHTPLS KLMKAYCERQ GLSMRQIRFR
61 FDGQPINETD TPAQLEMEDE DTIDVFQQQT GGVPESSLAG HSFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SUMO3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.42
- Highest tissue expression
- 112 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 112 nTPM
- cerebral cortex: 108 nTPM
- skeletal muscle: 107 nTPM
- hypothalamus: 101 nTPM
- basal ganglia: 101 nTPM
- amygdala: 93 nTPM
Single-cell type
- megakaryocytes: 427 nCPM
- hofbauer cells: 242 nCPM
- platelets: 242 nCPM
- parietal cells: 233 nCPM
- oocytes: 180 nCPM
- esophageal apical cells: 173 nCPM
Immune cell
- plasmacytoid DC: 163 nTPM
- total PBMC: 157 nTPM
- myeloid DC: 133 nTPM
- intermediate monocyte: 130 nTPM
- classical monocyte: 123 nTPM
- non-classical monocyte: 123 nTPM
Brain region
- hypothalamus: 110 nTPM
- thalamus: 103 nTPM
- basal ganglia: 93 nTPM
- cerebral cortex: 92 nTPM
- midbrain: 83 nTPM
- pons: 83 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.1
- gnomAD pLI
- 0.33
- gnomAD missense Z
- 1.28
- DepMap mean gene effect
- 0.14
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SUMO3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SUMO3 as an antibody target. Whether an autoantibody or antibody against SUMO3 could matter depends on whether native SUMO3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SUMO3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SUMO3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...